Silymarin in non alcoholic fatty liver disease
Open Access
- 1 January 2013
- journal article
- Published by Baishideng Publishing Group Inc. in World Journal of Hepatology
- Vol. 5 (3), 109-13
- https://doi.org/10.4254/wjh.v5.i3.109
Abstract
AIM: This study was undertaken to evaluate the hepatic effects of silybum marianum on non alcoholic fatty liver disease (NAFLD). METHODS: In 72 patients affected by NAFLD, main metabolic, hepatic and anti-inflammatory parameters were assayed after 3 mo of a restricted diet and before silymarin treatment (twice a day orally). The brightness of liver echography texture (hepatorenal ratio brightness) was also defined at same time. These evaluations were repeated after 6 mo of treatment. RESULTS: Serum levels of some metabolic and anti-inflammatory data nonsignificantly lowered after 6 mo of silymarin. On the contrary, Steato test, alanine aminotransferase (ALT), aspartate aminotransferase (AST) and gamma-glutamyl transpeptidase were significantly (P < 0.001) reduced. Instead, the AST/ALT ratio unchanged. Finally, the hepatorenal brightness ratio, as an index of hepatic steatosis, significantly (P < 0.05) dropped. CONCLUSION: The obtained results indicate that silymarin appears to be effective to reduce the biochemical, inflammatory and ultrasonic indices of hepatic steatosis. Some parameters indicative of early stage of atherosclerosis were also loweredKeywords
This publication has 43 references indexed in Scilit:
- The Effect of a Silybin-Vitamin E-Phospholipid Complex on Nonalcoholic Fatty Liver Disease: A Pilot StudyDigestive Diseases and Sciences, 2007
- Nonalcoholic fatty liver disease is a novel predictor of cardiovascular diseaseWorld Journal of Gastroenterology, 2007
- A new silybin-vitamin E-phospholipid complex improves insulin resistance and liver damage in patients with non-alcoholic fatty liver disease: preliminary observationsGut, 2006
- Body Fat Distribution, Liver Enzymes, and Risk of HypertensionHypertension, 2005
- Effects of Rosiglitazone and Metformin on Liver Fat Content, Hepatic Insulin Resistance, Insulin Clearance, and Gene Expression in Adipose Tissue in Patients With Type 2 DiabetesDiabetes, 2004
- Non‐alcoholic steatohepatitis in type 2 diabetes mellitusJournal of Gastroenterology and Hepatology, 2004
- Nonalcoholic fatty liver diseaseGastroenterology, 2002
- Nonalcoholic Fatty Liver Disease: Predictors of Nonalcoholic Steatohepatitis and Liver Fibrosis in the Severely ObeseGastroenterology, 2001
- Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitisJournal of Hepatology, 1999
- Nonalcoholic steatohepatitis: An expanded clinical entityGastroenterology, 1994